10 research outputs found
Π‘ΠΠΠ’ΠΠ Π’Π ΠΠΠ‘ΠΠΠΠΠΠΠΠ― ΠΠΠ’ΠΠ’Π ΠΠΠΠΠΠ‘ΠΠΠΠΠ ΠΠΠ’ΠΠΠΠΠ‘Π’Π ΠΠΠΠΠ₯ 5-ΠΠΠΠΠΠ-2-(1,3,4-Π’ΠΠΠΠΠΠΠΠ-2-ΠΠ)ΠΠΠΠΠΠ’ΠΠΠΠΠΠΠΠΠ-4-ΠΠΠΠ
The aim of work. Synthesize the new thiadiazolo-2-iminothiazolidin-4-ones and their 5-arylidene derivatives based on the heterocyclization reaction and Knoevenagel condensation and study their antitrypanosomal activity.Materials and Methods: organic synthesis, NMR spectroscopy, elemental analysis, pharmacological screening.Results and Discussion. Following the cyclization reaction of N-(1,3,4-thiadiazol-2-yl)substituted 2-chloroacetamides with ammonium thiocyanate in dry acetone the corresponding 2-imino-4-thiazolidinone derivatives have been obtained. Further chemical modification of synthesized methylene active 2-(1,3,4-thiadiazol-2-yl)imino-4-thiazolidinones was performed via Knoevenagel condensation with various aromatic or heterocyclic aldehydes, isatin or cinnamic aldehyde derivatives have yielded a series of 5-aryl(heteryl)ylidene- and 5-isatin(3-phenylpropene)ylidene derivatives as potential antitrypanosomal agents. The structure of obtained compounds was confirmed by NMR spectroscopy and elemental analysis.Conclusions. The results of in vitro screening of antitrypanosomal activity against Trypanosoma brucei gambiense (TBG) allowed us to identify four highly active compounds which owned essential trypanocidal effect with a range of values IC50 within 7.3-12.8 Β΅M.ΠΠ΅ΡΠ° ΡΠΎΠ±ΠΎΡΠΈ. ΠΠ° ΠΎΡΠ½ΠΎΠ²Ρ ΡΠ΅Π°ΠΊΡΡΠΉ Π³Π΅ΡΠ΅ΡΠΎΡΠΈΠΊΠ»ΡΠ·Π°ΡΡΡ ΡΠ° ΠΠ½ΡΠΎΠ²Π΅Π½Π°Π³Π΅Π»Ρ Π·Π΄ΡΠΉΡΠ½ΠΈΡΠΈ ΡΠΈΠ½ΡΠ΅Π· Π½ΠΎΠ²ΠΈΡ
ΡΡΠ°Π΄ΡΠ°Π·ΠΎΠ»ΠΎ-2-ΡΠΌΡΠ½ΠΎΡΡΠ°Π·ΠΎΠ»ΡΠ΄ΠΈΠ½-4-ΠΎΠ½ΡΠ² ΡΠ° ΡΡ
5-Π°ΡΠΈΠ»ΡΠ΄Π΅Π½ΠΏΠΎΡ
ΡΠ΄Π½ΠΈΡ
Π΄Π»Ρ ΡΠΊΡΠΈΠ½ΡΠ½Π³Ρ Π°Π½ΡΠΈΡΡΠΈΠΏΠ°Π½ΠΎΡΠΎΠΌΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ.ΠΠ°ΡΠ΅ΡΡΠ°Π»ΠΈ Ρ ΠΌΠ΅ΡΠΎΠ΄ΠΈ. ΠΡΠ³Π°Π½ΡΡΠ½ΠΈΠΉ ΡΠΈΠ½ΡΠ΅Π·, ΡΠΏΠ΅ΠΊΡΡΠΎΡΠΊΠΎΠΏΡΡ Π―ΠΠ , Π΅Π»Π΅ΠΌΠ΅Π½ΡΠ½ΠΈΠΉ Π°Π½Π°Π»ΡΠ·, ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΠΉ ΡΠΊΡΠΈΠ½ΡΠ½Π³.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΠΈ ΠΉ ΠΎΠ±Π³ΠΎΠ²ΠΎΡΠ΅Π½Π½Ρ. Π¦ΠΈΠΊΠ»ΡΠ·Π°ΡΡΡΡ N-(1,3,4-ΡΡΠ°Π΄ΡΠ°Π·ΠΎΠ»-2-ΡΠ»)Π·Π°ΠΌΡΡΠ΅Π½ΠΈΡ
2-Ρ
Π»ΠΎΡΠΎΠ°ΡΠ΅ΡΠ°ΠΌΡΠ΄ΡΠ² ΠΏΡΠ΄ Π΄ΡΡΡ Π°ΠΌΠΎΠ½ΡΡ ΡΡΠΎΡΡΠ°Π½Π°ΡΡ Π² ΡΠ΅ΡΠ΅Π΄ΠΎΠ²ΠΈΡΡ Π°ΡΠ΅ΡΠΎΠ½Ρ ΡΠΈΠ½ΡΠ΅Π·ΠΎΠ²Π°Π½ΠΎ ΡΠ΅ΡΡΡ Π½ΠΎΠ²ΠΈΡ
ΠΏΠΎΡ
ΡΠ΄Π½ΠΈΡ
2-ΡΠΌΡΠ½ΠΎΡΡΠ°Π·ΠΎΠ»ΡΠ΄ΠΈΠ½-4-ΠΎΠ½Ρ. ΠΠ°ΡΠ²Π½ΡΡΡΡ ΠΌΠ΅ΡΠΈΠ»Π΅Π½Π°ΠΊΡΠΈΠ²Π½ΠΎΡ Π³ΡΡΠΏΠΈ Π² ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½Ρ 5 ΡΡΠ°Π·ΠΎΠ»ΡΠ΄ΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠΈΠΊΠ»Ρ ΠΎΡΡΠΈΠΌΠ°Π½ΠΈΡ
2-(1,3,4-ΡΡΠ°Π΄ΡΠ°Π·ΠΎΠ»-2-ΡΠ»)ΡΠΌΡΠ½ΠΎΡΡΠ°Π·ΠΎΠ»ΡΠ΄ΠΈΠ½-4-ΠΎΠ½ΡΠ² Π΄ΠΎΠ·Π²ΠΎΠ»ΠΈΠ»Π° ΠΏΡΠΎΠ²Π΅ΡΡΠΈ ΡΡ
ΠΏΠΎΠ΄Π°Π»ΡΡΡ ΠΌΠΎΠ΄ΠΈΡΡΠΊΠ°ΡΡΡ Π² ΡΠΌΠΎΠ²Π°Ρ
ΡΠ΅Π°ΠΊΡΡΡ ΠΠ½ΡΠΎΠ²Π΅Π½Π°Π³Π΅Π»Ρ Π· ΡΡΠ·Π½ΠΎΠΌΠ°Π½ΡΡΠ½ΠΈΠΌΠΈ Π°ΡΠΈΠ»(Π³Π΅ΡΠ΅ΡΠΈΠ»)ΠΊΠ°ΡΠ±Π°Π»ΡΠ΄Π΅Π³ΡΠ΄Π°ΠΌΠΈ, ΡΠ·Π°ΡΠΈΠ½ΠΎΠΌ Π°Π±ΠΎ ΠΏΠΎΡ
ΡΠ΄Π½ΠΈΠΌΠΈ ΠΊΠΎΡΠΈΡΠ½ΠΎΠ³ΠΎ Π°Π»ΡΠ΄Π΅Π³ΡΠ΄Ρ Π· ΡΡΠ²ΠΎΡΠ΅Π½Π½ΡΠΌ ΡΠ΅ΡΡΠΉ Π²ΡΠ΄ΠΏΠΎΠ²ΡΠ΄Π½ΠΈΡ
5-Π°ΡΠΈΠ»(Π³Π΅ΡΠ΅ΡΠΈΠ»)ΡΠ»ΡΠ΄Π΅Π½- ΡΠ° 5-ΡΠ·Π°ΡΠΈΠ½(3-ΡΠ΅Π½ΡΠ»ΠΏΡΠΎΠΏΠ΅Π½)ΡΠ»ΡΠ΄Π΅Π½ΠΏΠΎΡ
ΡΠ΄Π½ΠΈΡ
ΡΠΊ ΠΏΠΎΡΠ΅Π½ΡΡΠΉΠ½ΠΈΡ
Π°Π½ΡΠΈΡΡΠΈΠΏΠ°Π½ΠΎΡΠΎΠΌΠ½ΠΈΡ
Π°Π³Π΅Π½ΡΡΠ². Π‘ΡΡΡΠΊΡΡΡΡ ΡΠΈΠ½ΡΠ΅Π·ΠΎΠ²Π°Π½ΠΈΡ
ΡΠΏΠΎΠ»ΡΠΊ ΠΏΡΠ΄ΡΠ²Π΅ΡΠ΄ΠΆΠ΅Π½ΠΎ Π΅Π»Π΅ΠΌΠ΅Π½ΡΠ½ΠΈΠΌ Π°Π½Π°Π»ΡΠ·ΠΎΠΌ ΡΠ° ΡΠΏΠ΅ΠΊΡΡΠΎΡΠΊΠΎΠΏΡΡΡ ΠΠΠ .ΠΠΈΡΠ½ΠΎΠ²ΠΊΠΈ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΠΈ ΡΠΊΡΠΈΠ½ΡΠ½Π³Ρ Π°Π½ΡΠΈΡΡΠΈΠΏΠ°Π½ΠΎΡΠΎΠΌΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ in vitro ΡΠΈΠ½ΡΠ΅Π·ΠΎΠ²Π°Π½ΠΈΡ
ΡΠΏΠΎΠ»ΡΠΊ Π½Π° ΡΡΠ°ΠΌΡ Trypanosoma brucei gambiense (TBG) Π΄ΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΈ ΡΠ΄Π΅Π½ΡΠΈΡΡΠΊΡΠ²Π°ΡΠΈ ΡΠΎΡΠΈΡΠΈ Π²ΠΈΡΠΎΠΊΠΎΠ°ΠΊΡΠΈΠ²Π½Ρ ΡΠΏΠΎΠ»ΡΠΊΠΈ, ΡΠΊΡ Π·Ρ Π·Π½Π°ΡΠ΅Π½Π½ΡΠΌΠΈ IC50 Π² ΠΌΠ΅ΠΆΠ°Ρ
7,3-12,8 ΠΌΠΊΠ Π²ΠΎΠ»ΠΎΠ΄ΡΠ»ΠΈ ΡΡΡΡΡΠ²ΠΈΠΌ ΡΡΠΈΠΏΠ°Π½ΠΎΡΠΈΠ΄Π½ΠΈΠΌ Π΅ΡΠ΅ΠΊΡΠΎΠΌ
Thiazolidinone motif in anticancer drug discovery. Experience of DH LNMU medicinal chemistry scientific group
The aim was analysis of 4-thiazolidinones and related heterocyclic systems anticancer activity data and formation of some rational design directions of potential anticancer agents. Synthetic research carried out in
Danylo Halytsky Lviv National Medical University (DH LNMU) allowed us to propose a whole number of
new molecular design directions of biological active 4-thiazolidinones and related heterocyclic systems, as
well as obtain directed library that numbers over 5000 of novel compounds. At the present time in vitro anticancer activity screening was carried out for more than 1000 compounds (US NCI protocol (Developmental
Therapeutic Program), among them 167 compounds showed high antitumor activity level. For the purpose
of optimization and rational design of highly active molecules with optimal Β«drug-likeΒ» characteristics and
discovering of possible mechanism of action SAR, QSAR analysis and molecular docking were carried out.
The ultimate aim of the project is creating of innovative synthetic drug with special mechanism of action and
sufficient pharmacological and toxicological features. Some aspects of structureβactivity relationships
were determined and structure design directions were proposed. The series of active compounds with high
anticancer activity and/or selectivity levels were selected.
Key words: synthesis, 4-thia(imida)zolidinones, thiopyrano[2,3-d]thiazoles, anticancer activity, (Q)SAR.ΠΠ΅ΡΠΎΡ ΡΠΎΠ±ΠΎΡΠΈ Π±ΡΠ² Π°Π½Π°Π»ΡΠ· ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡΠ² Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ ΠΏΡΠΎΡΠΈΠΏΡΡ
Π»ΠΈΠ½Π½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ 4-Π°Π·ΠΎΠ»ΡΠ΄ΠΎΠ½ΡΠ² Ρ ΡΠΏΠΎΡΡΠ΄Π½Π΅Π½ΠΈΡ
Π³Π΅ΡΠ΅ΡΠΎΡΠΈΠΊΠ»ΡΡΠ½ΠΈΡ
ΡΠΏΠΎΠ»ΡΠΊ ΡΠ° ΡΠΎΡΠΌΡΠ²Π°Π½Π½Ρ Π΄Π΅ΡΠΊΠΈΡ
Π½Π°ΠΏΡΡΠΌΠΊΡΠ² ΡΠ°ΡΡΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ·Π°ΠΉΠ½Ρ
ΠΏΠΎΡΠ΅Π½ΡΡΠΉΠ½ΠΈΡ
ΠΏΡΠΎΡΠΈΠΏΡΡ
Π»ΠΈΠ½Π½ΠΈΡ
Π°Π³Π΅Π½ΡΡΠ². Π‘ΠΈΠ½ΡΠ΅ΡΠΈΡΠ½Ρ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ, ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Ρ Ρ ΠΠΠΠ£ ΡΠΌΠ΅Π½Ρ ΠΠ°Π½ΠΈΠ»Π° ΠΠ°Π»ΠΈΡΡΠΊΠΎΠ³ΠΎ, Π΄ΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΈ Π·Π°ΠΏΡΠΎΠΏΠΎΠ½ΡΠ²Π°ΡΠΈ Π½ΠΈΠ·ΠΊΡ Π½ΠΎΠ²ΠΈΡ
ΡΠΏΡΡΠΌΡΠ²Π°Π½Ρ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ·Π°ΠΉΠ½Ρ
Π±ΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΎ Π°ΠΊΡΠΈΠ²Π½ΠΈΡ
4-ΡΡΠ°Π·ΠΎΠ»ΡΠ΄ΠΈΠ½ΠΎΠ½ΡΠ² ΡΠ° ΡΠΏΠΎΡΡΠ΄Π½Π΅Π½ΠΈΡ
Π³Π΅ΡΠ΅ΡΠΎΡΠΈΠΊΠ»ΡΡΠ½ΠΈΡ
ΡΠΈΡΡΠ΅ΠΌ, Π° ΡΠ°ΠΊΠΎΠΆ ΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈ ΡΡΠΎΠΊΡΡΠΎΠ²Π°Π½Ρ Π±ΡΠ±Π»ΡΠΎΡΠ΅ΠΊΡ, ΡΠΊΠ° Π½Π°ΡΠ°Ρ
ΠΎΠ²ΡΡ ΠΏΠΎΠ½Π°Π΄ 5000 Π½ΠΎΠ²ΠΈΡ
ΡΠΏΠΎΠ»ΡΠΊ. ΠΠ° ΡΠ΅ΠΉ ΡΠ°Ρ Π·Π΄ΡΠΉΡΠ½Π΅Π½ΠΎ
in vitro ΡΠΊΡΠΈΠ½ΡΠ½Π³ ΠΏΡΠΎΡΠΈΠΏΡΡ
Π»ΠΈΠ½Π½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΠΎΠ½Π°Π΄ 1000 ΡΠΏΠΎΠ»ΡΠΊ
(US NCI ΠΏΡΠΎΡΠΎΠΊΠΎΠ» Developmental Therapeutic Program), Π·-ΠΏΠΎΠΌΡΠΆ ΡΠΊΠΈΡ
167 ΡΠ΄Π΅Π½ΡΠΈΡΡΠΊΠΎΠ²Π°Π½ΠΎ ΡΠΊ ΡΠ°ΠΊΡ, ΡΠΎ ΠΌΠ°ΡΡΡ Π²ΠΈΡΠΎΠΊΡ ΠΏΡΠΎΡΠΈΡΠ°ΠΊΠΎΠ²Ρ Π°ΠΊΡΠΈΠ²Π½ΡΡΡΡ. ΠΠ»Ρ ΠΎΠΏΡΠΈΠΌΡΠ·Π°ΡΡΡ Ρ ΡΠ°ΡΡΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ·Π°ΠΉΠ½Ρ
Π²ΠΈΡΠΎΠΊΠΎΠ°ΠΊΡΠΈΠ²Π½ΠΈΡ
ΠΌΠΎΠ»Π΅ΠΊΡΠ» Π· ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΠΈΠΌΠΈ Β«Π»ΡΠΊΠΎΠΏΠΎΠ΄ΡΠ±Π½ΠΈΠΌΠΈΒ» Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ ΡΠ° Π²ΠΈΠ·Π½Π°ΡΠ΅Π½Π½Ρ ΠΌΠΎΠΆΠ»ΠΈΠ²ΠΎΠ³ΠΎ ΠΌΠ΅Ρ
Π°Π½ΡΠ·ΠΌΡ Π±ΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΎΡ Π΄ΡΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ SAR- Ρ QSAR-Π°Π½Π°Π»ΡΠ· Ρ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΈΠΉ Π΄ΠΎΠΊΡΠ½Π³.
ΠΡΠ½ΡΠ΅Π²ΠΎΡ ΠΌΠ΅ΡΠΎΡ ΠΏΡΠΎΠ΅ΠΊΡΡ Ρ ΡΡΠ²ΠΎΡΠ΅Π½Π½Ρ ΡΠ½Π½ΠΎΠ²Π°ΡΡΠΉΠ½ΠΎΠ³ΠΎ ΡΠΈΠ½ΡΠ΅ΡΠΈΡΠ½ΠΎΠ³ΠΎ Π»ΡΠΊΠ°ΡΡΡΠΊΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ Π· ΠΎΡΠΈΠ³ΡΠ½Π°Π»ΡΠ½ΠΈΠΌ ΠΌΠ΅Ρ
Π°Π½ΡΠ·ΠΌΠΎΠΌ Π΄ΡΡ
ΡΠ° Π΄ΠΎΡΡΠ°ΡΠ½ΡΠΌ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΠΌ Ρ ΡΠΎΠΊΡΠΈΠΊΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΠΌ ΠΏΡΠΎΡΡΠ»Π΅ΠΌ.
ΠΠ»ΡΡΠΎΠ²Ρ ΡΠ»ΠΎΠ²Π°: ΡΠΈΠ½ΡΠ΅Π·, 4-ΡΡΠ°(ΡΠΌΡΠ΄Π°)Π·ΠΎΠ»ΡΠ΄ΠΈΠ½ΠΎΠ½ΠΈ, ΡΡΠΎΠΏΡΡΠ°Π½ΠΎ[2,
3-d]ΡΡΠ°Π·ΠΎΠ»ΠΈ, ΠΏΡΠΎΡΠΈΠΏΡΡ
Π»ΠΈΠ½Π½Π° Π°ΠΊΡΠΈΠ²Π½ΡΡΡΡ, (Q)SAR.Π¦Π΅Π»Ρ ΡΠ°Π±ΠΎΡΡ ΡΠΎΡΡΠΎΡΠ»Π° Π² Π°Π½Π°Π»ΠΈΠ·Π΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ
ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ 4-Π°Π·ΠΎΠ»ΠΈΠ΄ΠΎΠ½ΠΎΠ² ΠΈ ΡΠΎΠ΄ΡΡΠ²Π΅Π½Π½ΡΡ
Π³Π΅ΡΠ΅ΡΠΎΡΠΈΠΊΠ»ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΡΡΠ΅ΠΌ ΠΈ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ Π½Π΅ΠΊΠΎΡΠΎΡΡΡ
Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠΉ ΡΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ·Π°ΠΉΠ½Π° ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»Π½ΡΡ
ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
Π°Π³Π΅Π½ΡΠΎΠ². Π‘ΠΈΠ½ΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΡΠ΅ Π²
ΠΠΠΠ£ ΠΈΠΌΠ΅Π½ΠΈ ΠΠ°Π½ΠΈΠ»Π° ΠΠ°Π»ΠΈΡΠΊΠΎΠ³ΠΎ, ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΈ ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠΈΡΡ ΡΡΠ΄ Π½ΠΎΠ²ΡΡ
Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠΉ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ·Π°ΠΉΠ½Π° Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Π°ΠΊΡΠΈΠ²Π½ΡΡ
4-ΡΠΈΠ°Π·ΠΎΠ»ΠΈΠ΄ΠΈΠ½ΠΎΠ½ΠΎΠ² ΠΈ ΡΠΎΠ΄ΡΡΠ²Π΅Π½Π½ΡΡ
Π³Π΅ΡΠ΅ΡΠΎΡΠΈΠΊΠ»ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΡΡΠ΅ΠΌ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΠΎΠ»ΡΡΠΈΡΡ ΡΡΠΎΠΊΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊΡ, Π½Π°ΡΡΠΈΡΡΠ²Π°ΡΡΡΡ Π±ΠΎΠ»Π΅Π΅ 5000 Π½ΠΎΠ²ΡΡ
ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ. ΠΠ° Π΄Π°Π½Π½ΡΠΉ ΠΌΠΎΠΌΠ΅Π½Ρ
ΠΎΡΡΡΠ΅ΡΡΠ²Π»Π΅Π½ in vitro ΡΠΊΡΠΈΠ½ΠΈΠ½Π³ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ
(US NCI ΠΏΡΠΎΡΠΎΠΊΠΎΠ» Developmental Therapeutic Program) Π±ΠΎΠ»Π΅Π΅
1000 ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ, ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ²ΡΠΈΠΉ ΠΈΠ΄Π΅Π½ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°ΡΡ 167 ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ Ρ Π²ΡΡΠΎΠΊΠΈΠΌ ΠΏΡΠΎΡΠΈΠ²ΠΎΡΠ°ΠΊΠΎΠ²ΡΠΌ ΡΡΡΠ΅ΠΊΡΠΎΠΌ. ΠΠ»Ρ ΠΎΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΠΈ ΠΈ ΡΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ·Π°ΠΉΠ½Π° Π²ΡΡΠΎΠΊΠΎΠ°ΠΊΡΠΈΠ²Π½ΡΡ
ΠΌΠΎΠ»Π΅ΠΊΡΠ» Ρ ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΡΠΌΠΈ Β«drug-likeΒ» Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ ΠΈ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Π²Π΅ΡΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠ° Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ SAR- ΠΈ
QSAR-Π°Π½Π°Π»ΠΈΠ· ΠΈ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΠΉ Π΄ΠΎΠΊΠΈΠ½Π³. ΠΠΎΠ½Π΅ΡΠ½Π°Ρ ΡΠ΅Π»Ρ ΠΏΡΠΎΠ΅ΠΊΡΠ° β
ΡΠΎΠ·Π΄Π°Π½ΠΈΠ΅ ΠΈΠ½Π½ΠΎΠ²Π°ΡΠΈΠ½Π½ΠΎΠ³ΠΎ ΡΠΈΠ½ΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ
ΡΡΠ΅ΡΠ΄ΡΠ²Π° Ρ ΠΎΡΠΈΠ³ΠΈΠ½Π°Π»ΡΠ½ΡΠΌ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΎΠΌ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ, Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΈ ΡΠΎΠΊΡΠΈΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΏΡΠΎΡΠΈΠ»Π΅ΠΌ.
ΠΠ»ΡΡΠ΅Π²ΡΠ΅ ΡΠ»ΠΎΠ²Π°: ΡΠΈΠ½ΡΠ΅Π·, 4-ΡΠΈΠ°(ΠΈΠΌΠΈΠ΄Π°)Π·ΠΎΠ»ΠΈΠ΄ΠΈΠ½ΠΎΠ½Ρ, ΡΠΈΠΎΠΏΠΈΡΠ°Π½ΠΎ[2,3-d]ΡΠΈΠ°Π·ΠΎΠ»Ρ, ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²Π°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ, (Q)SAR
Synthesis of novel 4H-1,2,4-triazole-3-thiol derivatives with 2-(2,6-dichlorophenylamino)benzyl fragment in molecules and their anti-inflammatory activity
Aim. The study of anti-inflammatory activity of novel 4H-1,2,4-triazole-3-thiol derivatives is one of the most priority direction of pharmacological investigation of mentioned heterocyclic system.
Methods and results. Based on the heterocyclization reaction of N-substituted thiosemicarbazides in alkaline medium the synthesis of novel non-condensed derivatives with 4H-1,2,4-triazole and 2-(2,6-dichlorophenylamino)benzyl fragments was carried out. Further chemical modification of synthesized 5-[2-(2,6-dichlorophenylamino)benzyl]-4H-1,2,4-triazole-3-thioles was performed via S-alkylation reactions with N-aryl(thiophene-2-yl)substituted 2-chloroacetamides and 2-chloro-1-(3,5-diaryl-4,5-dihydropyrazol-1-yl)ethanones. Structure of synthesized compounds was confirmed by the elemental analysis and 1H NMR spectral data.
Conclusions. The research of anti-inflammatory activity has been conducted on the carrageenan-induced edema of the ratβs extremities model. The results allow to identify highly active compounds 2-{5-[2-(2,6-dichloro-phenylamino)-benzyl]-4-ethyl-4Π-[1,2,4]triazol-3-ylsulfanyl}-N-(4-chlorophenyl)acetamide (compound 3b) and 2-{5-[2-(2,6-dichloro-phenylamino)-benzyl]-4-ethyl-4Π-[1,2,4]triazol-3-ylsulfanyl}-1-[5-(4-methoxy-phenyl)-3-(naphthalen-2-yl)-4,5-dihydro-pyrazol-1-yl]-ethanone (compound 5c) with evident antiexudative effect comparable with the same effect of diclofenac sodium
Π‘ΠΈΠ½ΡΠ΅Π· Π½ΠΎΠ²ΠΈΡ ΠΏΠΎΡ ΡΠ΄Π½ΠΈΡ 4Π-1,2,4-ΡΡΡΠ°Π·ΠΎΠ»-3-ΡΡΠΎΠ»Ρ Π· 2-(2,6-Π΄ΠΈΡ Π»ΠΎΡΠΎΡΠ΅Π½ΡΠ»Π°ΠΌΡΠ½ΠΎ)Π±Π΅Π½Π·ΠΈΠ»ΡΠ½ΠΈΠΌ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΎΠΌ Ρ ΠΌΠΎΠ»Π΅ΠΊΡΠ»Π°Ρ ΡΠ° ΡΡ Π½Ρ ΠΏΡΠΎΡΠΈΠ·Π°ΠΏΠ°Π»ΡΠ½Π° Π°ΠΊΡΠΈΠ²Π½ΡΡΡΡ
Aim. The study of anti-inflammatory activity of novel 4H-1,2,4-triazole-3-thiol derivatives is one of the most priority direction of pharmacological investigation of mentioned heterocyclic system.Methods and results. Based on the heterocyclization reaction of N-substituted thiosemicarbazides in alkaline medium the synthesis of novel non-condensed derivatives with 4H-1,2,4-triazole and 2-(2,6-dichlorophenylamino)benzyl fragments was carried out. Further chemical modification of synthesized 5-[2-(2,6-dichlorophenylamino)benzyl]-4H-1,2,4-triazole-3-thioles was performed via S-alkylation reactions with N-aryl(thiophene-2-yl)substituted 2-chloroacetamides and 2-chloro-1-(3,5-diaryl-4,5-dihydropyrazol-1-yl)ethanones. Structure of synthesized compounds was confirmed by the elemental analysis and 1H NMR spectral data.Conclusions. The research of anti-inflammatory activity has been conducted on the carrageenan-induced edema of the ratβs extremities model. The results allow to identify highly active compounds 2-{5-[2-(2,6-dichloro-phenylamino)-benzyl]-4-ethyl-4Π-[1,2,4]triazol-3-ylsulfanyl}-N-(4-chlorophenyl)acetamide (compound 3b) and 2-{5-[2-(2,6-dichloro-phenylamino)-benzyl]-4-ethyl-4Π-[1,2,4]triazol-3-ylsulfanyl}-1-[5-(4-methoxy-phenyl)-3-(naphthalen-2-yl)-4,5-dihydro-pyrazol-1-yl]-ethanone (compound 5c) with evident antiexudative effect comparable with the same effect of diclofenac sodium.ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π½ΠΎΠ²ΡΡ
ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΡΡ
4Π-1,2,4-ΡΡΠΈΠ°Π·ΠΎΠ»-3-ΡΠΈΠΎΠ»Π° ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΏΡΠΈΠΎΡΠΈΡΠ΅ΡΠ½ΡΡ
Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠΉ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΠΊΠ°Π·Π°Π½Π½ΠΎΠΉ Π³Π΅ΡΠ΅ΡΠΎΡΠΈΠΊΠ»ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ. ΠΠ° ΠΎΡΠ½ΠΎΠ²Π΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π³Π΅ΡΠ΅ΡΠΎΡΠΈΠΊΠ»ΠΈΠ·Π°ΡΠΈΠΈ N-Π·Π°ΠΌΠ΅ΡΡΠ½Π½ΡΡ
ΡΠΈΠΎΡΠ΅ΠΌΠΈΠΊΠ°ΡΠ±Π°Π·ΠΈΠ΄ΠΎΠ² Π² ΡΠ΅Π»ΠΎΡΠ½ΠΎΠΉ ΡΡΠ΅Π΄Π΅ ΠΏΠΎΠ»ΡΡΠ΅Π½Π° Π³ΡΡΠΏΠΏΠ° Π½ΠΎΠ²ΡΡ
Π½Π΅ΠΊΠΎΠ½Π΄Π΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΡ
4Π-1,2,4-ΡΡΠΈΠ°Π·ΠΎΠ»ΡΠ½ΡΠΉ ΠΈ 2-(2,6-Π΄ΠΈΡ
Π»ΠΎΡΠΎΡΠ΅Π½ΠΈΠ»Π°ΠΌΠΈΠ½ΠΎ)Π±Π΅Π½Π·ΠΈΠ»ΡΠ½ΡΠΉ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΡ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π° Ρ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΡΠΈΠ½ΡΠ΅Π·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
5-[2-(2,6-Π΄ΠΈΡ
Π»ΠΎΡΠΎΡΠ΅Π½ΠΈΠ»Π°ΠΌΠΈΠ½ΠΎ)Π±Π΅Π½Π·ΠΈΠ»]-4Π-1,2,4-ΡΡΠΈΠ°Π·ΠΎΠ»-3-ΡΠΈΠΎΠ»ΠΎΠ² Π² ΡΠ΅Π°ΠΊΡΠΈΡΡ
S-Π°Π»ΠΊΠΈΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Ρ N-Π°ΡΠΈΠ»(ΡΠΈΠΎΡΠ΅Π½-2-ΠΈΠ»)Π·Π°ΠΌΠ΅ΡΡΠ½Π½ΡΠΌΠΈ 2-Ρ
Π»ΠΎΡΠΎΠ°ΡΠ΅ΡΠ°ΠΌΠΈΠ΄Π°ΠΌΠΈ ΠΈ 2-Ρ
Π»ΠΎΡΠΎ-1-(3,5-Π΄ΠΈΠ°ΡΠΈΠ»-4,5-Π΄ΠΈΠ³ΠΈΠ΄ΡΠΎΠΏΠΈΡΠ°Π·ΠΎΠ»-1-ΠΈΠ»)ΡΡΠ°Π½ΠΎΠ½Π°ΠΌΠΈ. Π‘ΡΡΡΠΊΡΡΡΠ° ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½Π° ΡΠ»Π΅ΠΌΠ΅Π½ΡΠ½ΡΠΌ Π°Π½Π°Π»ΠΈΠ·ΠΎΠΌ ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΠΠ ΡΠΏΠ΅ΠΊΡΡΠΎΡΠΊΠΎΠΏΠΈΠΈ. ΠΡΠΎΠ²Π΅Π΄ΡΠ½ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π½Π° ΠΌΠΎΠ΄Π΅Π»ΠΈ ΠΊΠ°ΡΡΠ°Π³Π΅Π½ΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΠΎΡΡΠΊΠ° Ρ ΠΊΡΡΡ, ΠΊΠΎΡΠΎΡΡΠΉ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ» ΠΈΠ΄Π΅Π½ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°ΡΡ Π΄Π²Π° Π²ΡΡΠΎΠΊΠΎΠ°ΠΊΡΠΈΠ²Π½ΡΡ
ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΡ: 2-{5-[2-(2,6-Π΄ΠΈΡ
Π»ΠΎΡΠΎΡΠ΅Π½ΠΈΠ»Π°ΠΌΠΈΠ½ΠΎ)Π±Π΅Π½Π·ΠΈΠ»]-4-ΡΡΠΈΠ»-4Π-1,2,4-ΡΡΠΈΠ°Π·ΠΎΠ»-3-ΠΈΠ»ΡΡΠ»ΡΡΠ°Π½ΠΈΠ»}-N-(4-Ρ
Π»ΠΎΡΠΎΡΠ΅Π½ΠΈΠ»)Π°ΡΠ΅ΡΠ°ΠΌΠΈΠ΄ (ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠ΅ 3b) ΠΈ 2-{5-[2-(2,6-Π΄ΠΈΡ
Π»ΠΎΡΠΎΡΠ΅Π½ΠΈΠ»Π°ΠΌΠΈΠ½ΠΎ)Π±Π΅Π½Π·ΠΈΠ»]-4-ΡΡΠΈΠ»-4Π-1,2,4-ΡΡΠΈΠ°Π·ΠΎΠ»-3-ΠΈΠ»ΡΡΠ»ΡΡΠ°Π½ΠΈΠ»}-1-[5-(4-ΠΌΠ΅ΡΠΎΠΊΡΠΈΡΠ΅Π½ΠΈΠ»)-3-(Π½Π°ΡΡΠ°Π»Π΅Π½-2-ΠΈΠ»)-4,5-Π΄ΠΈΠ³ΠΈΠ΄ΡΠΎΠΏΠΈΡΠ°Π·ΠΎΠ»-1-ΠΈΠ»]ΡΡΠ°Π½ΠΎΠ½ (ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠ΅ 5c), ΠΏΡΠΎΡΠ²Π»ΡΡΡΠΈΡ
Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠ΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΡΡΡΠ½ΠΎΠ΅ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅, ΡΠΎΠΏΠΎΡΡΠ°Π²ΠΈΠΌΠΎΠ΅ Ρ Π°Π½Π°Π»ΠΎΠ³ΠΈΡΠ½ΡΠΌ ΡΡΡΠ΅ΠΊΡΠΎΠΌ Π΄ΠΈΠΊΠ»ΠΎΡΠ΅Π½Π°ΠΊΠ° Π½Π°ΡΡΠΈΡ.ΠΠΈΠ²ΡΠ΅Π½Π½Ρ ΠΏΡΠΎΡΠΈΠ·Π°ΠΏΠ°Π»ΡΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π½ΠΎΠ²ΠΈΡ
ΠΏΠΎΡ
ΡΠ΄Π½ΠΈΡ
4Π-1,2,4-ΡΡΡΠ°Π·ΠΎΠ»-3-ΡΡΠΎΠ»Ρ Ρ ΠΎΠ΄Π½ΠΈΠΌ ΡΠ· ΠΏΡΡΠΎΡΠΈΡΠ΅ΡΠ½ΠΈΡ
Π½Π°ΠΏΡΡΠΌΡΠ² ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΡ
Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Ρ Π²ΠΊΠ°Π·Π°Π½ΠΎΡ Π³Π΅ΡΠ΅ΡΠΎΡΠΈΠΊΠ»ΡΡΠ½ΠΎΡ ΡΠΈΡΡΠ΅ΠΌΠΈ. ΠΠ° ΠΎΡΠ½ΠΎΠ²Ρ ΡΠ΅Π°ΠΊΡΡΡ Π³Π΅ΡΠ΅ΡΠΎΡΠΈΠΊΠ»ΡΠ·Π°ΡΡΡ N-Π·Π°ΠΌΡΡΠ΅Π½ΠΈΡ
ΡΡΠΎΡΠ΅ΠΌΡΠΊΠ°ΡΠ±Π°Π·ΠΈΠ΄ΡΠ² Ρ Π»ΡΠΆΠ½ΠΎΠΌΡ ΡΠ΅ΡΠ΅Π΄ΠΎΠ²ΠΈΡΡ ΠΎΠ΄Π΅ΡΠΆΠ°Π»ΠΈ Π³ΡΡΠΏΡ Π½ΠΎΠ²ΠΈΡ
Π½Π΅ΠΊΠΎΠ½Π΄Π΅Π½ΡΠΎΠ²Π°Π½ΠΈΡ
ΡΠΏΠΎΠ»ΡΠΊ, ΡΠΎ ΠΏΠΎΡΠ΄Π½ΡΡΡΡ 4Π-1,2,4-ΡΡΡΠ°Π·ΠΎΠ»ΡΠ½ΠΈΠΉ Ρ 2-(2,6-Π΄ΠΈΡ
Π»ΠΎΡΠΎΡΠ΅Π½ΡΠ»Π°ΠΌΡΠ½ΠΎ)Π±Π΅Π½Π·ΠΈΠ»ΡΠ½ΠΈΠΉ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΈ. ΠΠ΄ΡΠΉΡΠ½ΠΈΠ»ΠΈ Ρ
ΡΠΌΡΡΠ½Ρ ΠΌΠΎΠ΄ΠΈΡΡΠΊΠ°ΡΡΡ ΡΠΈΠ½ΡΠ΅Π·ΠΎΠ²Π°Π½ΠΈΡ
5-[2-(2,6-Π΄ΠΈΡ
Π»ΠΎΡΠΎΡΠ΅Π½ΡΠ»Π°ΠΌΡΠ½ΠΎ)Π±Π΅Π½Π·ΠΈΠ»]-4Π-1,2,4-ΡΡΡΠ°Π·ΠΎΠ»-3-ΡΡΠΎΠ»ΡΠ² Ρ ΡΠ΅Π°ΠΊΡΡΡΡ
S-Π°Π»ΠΊΡΠ»ΡΠ²Π°Π½Π½Ρ Π· N-Π°ΡΠΈΠ»(ΡΡΠΎΡΠ΅Π½-2-ΡΠ»)Π·Π°ΠΌΡΡΠ΅Π½ΠΈΠΌΠΈ 2-Ρ
Π»ΠΎΡΠΎΠ°ΡΠ΅ΡΠ°ΠΌΡΠ΄Π°ΠΌΠΈ ΡΠ° 2-Ρ
Π»ΠΎΡΠΎ-1-(3,5-Π΄ΡΠ°ΡΠΈΠ»-4,5-Π΄ΠΈΠ³ΡΠ΄ΡΠΎΠΏΡΡΠ°Π·ΠΎΠ»-1-ΡΠ»)Π΅ΡΠ°Π½ΠΎΠ½Π°ΠΌΠΈ. Π‘ΡΡΡΠΊΡΡΡΡ ΡΠΈΠ½ΡΠ΅Π·ΠΎΠ²Π°Π½ΠΈΡ
ΡΠΏΠΎΠ»ΡΠΊ ΠΏΡΠ΄ΡΠ²Π΅ΡΠ΄ΠΆΠ΅Π½ΠΎ Π΅Π»Π΅ΠΌΠ΅Π½ΡΠ½ΠΈΠΌ Π°Π½Π°Π»ΡΠ·ΠΎΠΌ Ρ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΠΠ ΡΠΏΠ΅ΠΊΡΡΠΎΡΠΊΠΎΠΏΡΡ. ΠΠ΄ΡΠΉΡΠ½ΠΈΠ»ΠΈ ΡΠΊΡΠΈΠ½ΡΠ½Π³ ΠΏΡΠΎΡΠΈΠ·Π°ΠΏΠ°Π»ΡΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π½Π° ΠΌΠΎΠ΄Π΅Π»Ρ ΠΊΠ°ΡΠ°Π³Π΅Π½ΡΠ½ΠΎΠ²ΠΎΠ³ΠΎ Π½Π°Π±ΡΡΠΊΡ Π² ΡΡΡΡΠ², ΡΠΎ Π΄Π°Π»ΠΎ ΠΌΠΎΠΆΠ»ΠΈΠ²ΡΡΡΡ ΡΠ΄Π΅Π½ΡΠΈΡΡΠΊΡΠ²Π°ΡΠΈ Π΄Π²Ρ Π²ΠΈΡΠΎΠΊΠΎΠ°ΠΊΡΠΈΠ²Π½Ρ ΡΠΏΠΎΠ»ΡΠΊΠΈ: 2-{5-[2-(2,6-Π΄ΠΈΡ
Π»ΠΎΡΠΎΡΠ΅Π½ΡΠ»Π°ΠΌΡΠ½ΠΎ)Π±Π΅Π½Π·ΠΈΠ»]-4-Π΅ΡΠΈΠ»-4Π-1,2,4-ΡΡΡΠ°Π·ΠΎΠ»-3-ΡΠ»ΡΡΠ»ΡΡΠ°Π½ΡΠ»}-N-(4-Ρ
Π»ΠΎΡΠΎΡΠ΅Π½ΡΠ»)Π°ΡΠ΅ΡΠ°ΠΌΡΠ΄ (ΡΠΏΠΎΠ»ΡΠΊΠ° 3b) ΡΠ° 2-{5-[2-(2,6-Π΄ΠΈΡ
Π»ΠΎΡΠΎΡΠ΅Π½ΡΠ»Π°ΠΌΡΠ½ΠΎ)Π±Π΅Π½Π·ΠΈΠ»]-4-Π΅ΡΠΈΠ»-4Π-1,2,4-ΡΡΡΠ°Π·ΠΎΠ»-3-ΡΠ»ΡΡΠ»ΡΡΠ°Π½ΡΠ»}-1-[5-(4-ΠΌΠ΅ΡΠΎΠΊΡΠΈΡΠ΅Π½ΡΠ»)-3-(Π½Π°ΡΡΠ°Π»Π΅Π½-2-ΡΠ»)-4,5-Π΄ΠΈΠ³ΡΠ΄ΡΠΎΠΏΡΡΠ°Π·ΠΎΠ»-1-ΡΠ»]Π΅ΡΠ°Π½ΠΎΠ½ (ΡΠΏΠΎΠ»ΡΠΊΠ° 5c), ΠΊΠΎΡΡΡ Π²ΠΈΡΠ²Π»ΡΡΡΡ Π²ΠΈΡΠ°Π·Π½Ρ ΠΏΡΠΎΡΠΈΠ½Π°Π±ΡΡΠΊΠΎΠ²Ρ Π΄ΡΡ, ΡΠΎ Ρ ΡΠΏΡΠ²ΠΌΡΡΠ½ΠΎΡ Π· Π°Π½Π°Π»ΠΎΠ³ΡΡΠ½ΠΈΠΌ Π΅ΡΠ΅ΠΊΡΠΎΠΌ Π΄ΠΈΠΊΠ»ΠΎΡΠ΅Π½Π°ΠΊΡ Π½Π°ΡΡΡΡ
SYNTHESIS AND ANTI-INFLAMMATORY ACTIVITY EVALUATION OF RHODANINE DERIVATIVES WITH 2-(2,6-DICHLOROPHENYLAMINO)-PHENYLACETAMIDE FRAGMENT IN MOLECULES
The aim of work. Synthesize the new 5-ylidenerhodanine derivatives with diclofenac fragment in position 3 based on the heterocyclization reaction and Knoevenagel condensation for screening their anti-inflammatory activity.
Materials and Methods. Organic synthesis, NMR spectroscopy, elemental analysis, pharmacological screening, SAR-analysis.
Results and Discussion. The interaction of 2-(2,6-dichlorophenylamino)phenylacetic acid hydrazide and thiocarbonyl-bis-thioglycolic acid in ethanol medium resulted in rhodanine derivative with fragment of anti-inflammatory drug Β«DiclofenacΒ» in position 3. Considering the presence of an active methylene group in position 5 the further chemical modification of synthesized rhodanine was performed via Knoevenagel condensation with various aromatic aldehydes, isatin or cinnamic aldehyde derivatives have yielded a series of 5-arylidene- and 5-isatin(3-phenylpropene)ylidene derivatives for pharmacological screening on antiexudative action. The structure of obtained compounds was confirmed by NMR spectroscopy and elemental analysis.
Conclusions. The results of anti-inflammatory activity investigation of synthesized compounds allowed us to identify three highly active derivatives which was appropriate to the reference nonsteroidal inflammatory drug Β«Diclofenac SodiumΒ» by indicator of inhibition of inflammatory reaction (42,4-45,3%)
Study of antineoplastic action of novel isomeric derivatives of 4-thiazolidinone
Pyrazole- and aryl-substituted derivatives of 4-thiazolidinone belong to a perspective group of compounds with potential antitumor action. Earlier, we have demonstrated high toxicity in vitro of several 4-thiazolidinones derivatives towards tumor cell lines. To further enhance the antitumor activity of novel 4-thiazolidinones, their chemical scaffold was optimized, and new pyrazole-thiazolidinones were synthesized. That allowed us to combine in one molecule the potential pharmacophore centres of previously tested compounds. As a result, βhybridβ 4-thiazolidinones exhibit higher toxicity in vitro toward tumor cells of various origin. The molecular mechanisms of antineoplastic activity of these compounds and intensity of induction of apoptosis strongly depended on the position of the substituent in the thiazolidinone cycle. In particular, Les-3661 compound, containing pyrazoline fragment in the 4th position of thiazolidinone core, exhibits 14 times higher cytotoxic activity towards tumor cells (LC50 = 3 Β΅M) in comparison to its 2-substituted isomer Les-3713 (LC50 = 42 Β΅M). It is demonstrated that in terms of underlying molecular mechanisms for cytotoxic effect the Les-3661 compound induced caspase-8 and caspase-9 dependent mixed-type of apoptosis, while Les-3713 induced apoptosis mediated only by the caspase-8
Comparative study of the cytotoxic properties of isatin-containing derivatives of 4-thiazolidinone with different structure toward human tumor cells in vitro
Compounds on the basis of 4-thiazolidinone and its isatin-containing derivatives are characterized by a broad spectrum of biological activities and are potential antineoplastic agents. We have shown that the combination of 4-thiazolidinone and isatine (1H-indole-2,3-dione) in one molecule enhances the cytotoxic action of novel compounds towards lukemic and carcinoma cells in vitro. The level of cytotoxic action of ID-3833, ID-4522, ID-4523, ID-4524, ID-4525, ID-4526, ID-4527 compounds strongly depends on the presence of a halogen in the 5th position of the indoline moiety and the type of the atom (chlorine or bromine) in the aryl groups in the 3rd and 5th positions in pyrazoline moiety. Compound ID-3833 demonstrates the highest activity, which can be associated with the presence of bromine in the 5th position of indoline and 4-methoxyphenyl in the 5th position of pyrazoline and naphthyl in the 3rd position of pyrazoline. ID-4524 compound, whose molecule contains 5-bromindoline and two para-chlorophenyl groups also possessed high cytotoxic effect towards tumor cells. At the same time, ID-4522 compound was found to possess the lowest cytotoxic activity towards tumor cells. Like ID-4524 compound, it is characterized by the presence of two para-chlorophenyl groups in 3rd and 5th position of pyrazoline in isatin-pyrazoline-thiazolidinonr system, but it does not contain halogen in the 5th position of the indoline moiety. Thus, cytotoxic effect of isatin-containing 4-thiazolidinones mostly depends on the presence of halogen in the 5th position of the indoline, and the type of halogen in the 3rd and 5th position of the aryl groups of pirazoline cycle. All of these substances induce apoptosis in tumor cells. It has been shown that the ID-3833 substance induces apoptosis of mixed type, which includes the ER stress and mitochondrial apoptosis. The identified structure-functional relationships of 4-thiazolidones will be of high importance for further enhancement of their antineoplastic activity towards tumor cells
Enhanced Proapoptotic Effects of Water Dispersed Complexes of 4-Thiazolidinone-Based Chemotherapeutics with a PEG-Containing Polymeric Nanocarrier
Abstract Aim To study whether water formulation of the complex of 4-thiazolidinone derivatives with a PEG-containing polymeric nanocarrier enhances their pro-apoptotic action towards rat glioma C6 cells. Methods Mechanisms of antineoplastic effects of 4-thiazolidinone derivatives were investigated in vitro with rat glioma C6 cells. Cell nativity, cell cycling pattern, and Annexin V expression were evaluated and DNA damage was estimated by DNA comet analysis. A novel water-based formulation of 4-thiazolidinone derivatives complexed with a polymeric nanocarrier was utilized for enhancing pro-apoptotic action towards C6 cells. Results The studied 4-thiazolidinone derivatives use apoptosis mechanisms for killing rat glioma C6 cells, as confirmed by FACS analysis of these cells in pre-G1 stage, the appearance of Annexin V positive C6 cells, and an increased number of DNA comets of higher classes. Complexation of the studied compounds with a PEG-containing polymeric nanocarrier significantly increased pro-apoptotic effects in rat glioma C6 cells measured by all methods mentioned above. Conclusion Complexation of 4-thiazolidinone derivatives with a PEG-containing polymeric nanocarrier provided them with water solubility and enhanced pro-apoptotic effects in rat glioma C6 cells